Shree Ganesh BioTech India Ltd
BSE:539470
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/GP
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Valuation Scenarios
If EV/GP returns to its 3-Year Average (54), the stock would be worth ₹-1.13 (285% downside from current price).
| Scenario | EV/GP Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -29.1 | ₹0.61 |
0%
|
| 3-Year Average | 54 | ₹-1.13 |
-285%
|
| 5-Year Average | 54 | ₹-1.13 |
-285%
|
| Industry Average | 8 | ₹-0.17 |
-127%
|
| Country Average | 6.5 | ₹-0.14 |
-122%
|
Forward EV/GP
Today’s price vs future gross profit
Peer Comparison
| Market Cap | EV/GP | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
S
|
Shree Ganesh BioTech India Ltd
BSE:539470
|
243.2m INR | -29.1 | -62.2 | |
| US |
G
|
GE Vernova LLC
NYSE:GEV
|
285.6B USD | 0 | 0 | |
| UK |
E
|
Eight Capital Partners PLC
F:ECS
|
158.4B EUR | 0 | 0 | |
| US |
C
|
China Industrial Group Inc
OTC:CIND
|
121B USD | 2 198.6 | 4 020.7 | |
| NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
100.2B ZAR | 13.2 | 10.4 | |
| US |
F
|
Fintech Ecosystem Development Corp
NASDAQ:FEXD
|
67.9B USD | 0 | 38 368.9 | |
| US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
59.7B USD | 0 | 0 | |
| CH |
G
|
Galderma Group AG
SIX:GALD
|
38.4B CHF | 0 | 0 | |
| US |
|
Coupang Inc
F:788
|
31.4B EUR | 3.1 | 173.5 | |
| US |
|
Symbotic Inc
NASDAQ:SYM
|
35.5B USD | 70.5 | -3 256.9 | |
| ZA |
V
|
Vukile Property Fund Ltd
JSE:VKE
|
29.7B ZAR | 14.8 | 6.9 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 4.1 |
| Median | 6.5 |
| 70th Percentile | 10.8 |
| Max | 34 392.2 |
Other Multiples
Shree Ganesh BioTech India Ltd
Glance View
Shree Ganesh Biotech (India) Ltd. is a biotech firm, which engages in the production, processing, and marketing of hybrid seeds. The company is headquartered in Kolkata, West Bengal. The company went IPO on 2015-11-24. The firm is also involved in the business of tissue culture plant. The company is a provider of crop solutions to the farmer by supplying high yielding hybrid seeds and crop management, namely micronutrients and bioproducts. The firm is also engaged in research and development in the areas of superior breeding programs and biotechnology tools. The firm sells its products to the farmers in West Bengal, Odisha and Bihar.
